MX375716B - Método para tratar adenocarcinoma de pulmón. - Google Patents

Método para tratar adenocarcinoma de pulmón.

Info

Publication number
MX375716B
MX375716B MX2016013600A MX2016013600A MX375716B MX 375716 B MX375716 B MX 375716B MX 2016013600 A MX2016013600 A MX 2016013600A MX 2016013600 A MX2016013600 A MX 2016013600A MX 375716 B MX375716 B MX 375716B
Authority
MX
Mexico
Prior art keywords
lung adenocarcinoma
ros1
patient
treating lung
cancer
Prior art date
Application number
MX2016013600A
Other languages
English (en)
Spanish (es)
Other versions
MX2016013600A (es
Inventor
Dana T Aftab
Peiwen Yu
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53055132&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX375716(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of MX2016013600A publication Critical patent/MX2016013600A/es
Publication of MX375716B publication Critical patent/MX375716B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2016013600A 2014-04-25 2015-04-27 Método para tratar adenocarcinoma de pulmón. MX375716B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461984599P 2014-04-25 2014-04-25
PCT/US2015/027800 WO2015164869A1 (en) 2014-04-25 2015-04-27 Method of treating lung adenocarcinoma

Publications (2)

Publication Number Publication Date
MX2016013600A MX2016013600A (es) 2017-04-27
MX375716B true MX375716B (es) 2025-03-06

Family

ID=53055132

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013600A MX375716B (es) 2014-04-25 2015-04-27 Método para tratar adenocarcinoma de pulmón.

Country Status (21)

Country Link
US (1) US20170042880A1 (cg-RX-API-DMAC7.html)
EP (2) EP3134084B1 (cg-RX-API-DMAC7.html)
JP (2) JP6696908B2 (cg-RX-API-DMAC7.html)
KR (1) KR102474701B1 (cg-RX-API-DMAC7.html)
CN (1) CN106488768A (cg-RX-API-DMAC7.html)
AR (1) AR100191A1 (cg-RX-API-DMAC7.html)
AU (1) AU2015249232B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016024672A2 (cg-RX-API-DMAC7.html)
CA (1) CA2946416C (cg-RX-API-DMAC7.html)
DK (1) DK3134084T3 (cg-RX-API-DMAC7.html)
EA (1) EA035223B1 (cg-RX-API-DMAC7.html)
ES (1) ES2874875T3 (cg-RX-API-DMAC7.html)
HU (1) HUE054557T2 (cg-RX-API-DMAC7.html)
IL (1) IL248408B (cg-RX-API-DMAC7.html)
MX (1) MX375716B (cg-RX-API-DMAC7.html)
PL (1) PL3134084T3 (cg-RX-API-DMAC7.html)
PT (1) PT3134084T (cg-RX-API-DMAC7.html)
SG (1) SG11201608657QA (cg-RX-API-DMAC7.html)
TW (1) TWI724988B (cg-RX-API-DMAC7.html)
UA (1) UA121655C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015164869A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140025496A (ko) 2011-05-02 2014-03-04 엑셀리시스, 인코포레이티드 암 및 뼈 암 통증의 치료방법
JP6666849B2 (ja) 2014-03-17 2020-03-18 エグゼリクシス， インコーポレイテッド カボザンチニブ製剤の投与
WO2016019285A1 (en) 2014-07-31 2016-02-04 Exelixis, Inc. Method of preparing fluorine-18 labeled cabozantinib and its analogs
KR102634247B1 (ko) 2014-08-05 2024-02-05 엑셀리시스, 인코포레이티드 다발성 골수종을 치료하기 위한 약물 병용물
CA3020749A1 (en) 2016-04-15 2017-10-19 Exelixis, Inc. Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
CN107353246A (zh) * 2016-12-27 2017-11-17 辅仁药业集团熙德隆肿瘤药品有限公司 一种制备抗肿瘤药物卡博替尼的方法
CA3059119C (en) * 2017-05-31 2024-01-23 F. Hoffman-La Roche Ag Multiplex pcr detection of alk, ret, and ros fusions
MX2019014298A (es) 2017-06-09 2020-02-03 Exelixis Inc Formas de dosificacion liquida para tratar el cancer.
CN107541550A (zh) * 2017-08-21 2018-01-05 上海派森诺生物科技股份有限公司 人ros1融合基因检测方法
JP7279026B2 (ja) * 2017-09-20 2023-05-22 メルサナ セラピューティクス インコーポレイテッド Ｎａｐｉ２ｂ標的化療法に対する応答を予測するための組成物および方法
SG11202006921PA (en) 2018-01-26 2020-08-28 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
EP3743417A1 (en) 2018-01-26 2020-12-02 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
WO2019148036A1 (en) 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
AR119069A1 (es) * 2019-06-04 2021-11-24 Exelixis Inc Compuestos para el tratamiento de trastornos dependientes de quinasas
DE102020005002A1 (de) * 2020-08-17 2022-02-17 Epo Experimentelle Pharmakologie & Onkologie Berlin-Buch Gmbh Mittel zur Therapie von Tumorerkrankungen

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5447841A (en) 1986-01-16 1995-09-05 The Regents Of The Univ. Of California Methods for chromosome-specific staining
US5756696A (en) 1986-01-16 1998-05-26 Regents Of The University Of California Compositions for chromosome-specific staining
US5491224A (en) 1990-09-20 1996-02-13 Bittner; Michael L. Direct label transaminated DNA probe compositions for chromosome identification and methods for their manufacture
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
EP2392565B1 (en) * 2003-09-26 2014-03-19 Exelixis, Inc. c-Met modulators and methods of use
US20100143918A1 (en) 2007-01-19 2010-06-10 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
WO2008083319A1 (en) 2006-12-29 2008-07-10 Il Yang Pharmaceutical Company, Ltd. Solid state forms of enantiopure ilaprazole
US9096855B2 (en) 2007-10-18 2015-08-04 Cell Signaling Technology, Inc. Translocation and mutant ROS kinase in human non-small cell lung carcinoma
PT2387563E (pt) * 2009-01-16 2013-03-25 Exelixis Inc Sal de malato de n-(4-{[6,7-bis(metiloxi)quinolin-4- il]oxi}fenil)-n¿-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, e suas formas cristalinas para o tratamento de cancro
EP2881402B1 (en) 2009-02-12 2017-05-10 Cell Signaling Technology, Inc. Mutant ROS expression in human liver cancer
TWI585088B (zh) * 2012-06-04 2017-06-01 第一三共股份有限公司 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物
WO2014039971A1 (en) * 2012-09-07 2014-03-13 Exelixis, Inc. Inhibitors of met, vegfr and ret for use in the treatment of lung adenocarcinoma

Also Published As

Publication number Publication date
EA035223B1 (ru) 2020-05-18
NZ725576A (en) 2021-03-26
AR100191A1 (es) 2016-09-14
HUE054557T2 (hu) 2021-09-28
IL248408A0 (en) 2016-11-30
WO2015164869A1 (en) 2015-10-29
EP3134084A1 (en) 2017-03-01
CA2946416A1 (en) 2015-10-29
JP6696908B2 (ja) 2020-05-20
KR20160147934A (ko) 2016-12-23
US20170042880A1 (en) 2017-02-16
CA2946416C (en) 2022-07-19
CN106488768A (zh) 2017-03-08
PT3134084T (pt) 2021-05-11
TWI724988B (zh) 2021-04-21
AU2015249232B2 (en) 2020-06-25
DK3134084T3 (da) 2021-05-03
PL3134084T3 (pl) 2021-09-27
AU2015249232A1 (en) 2016-11-10
EA201692150A1 (ru) 2017-02-28
SG11201608657QA (en) 2016-11-29
UA121655C2 (uk) 2020-07-10
MX2016013600A (es) 2017-04-27
TW201622723A (zh) 2016-07-01
IL248408B (en) 2022-06-01
BR112016024672A2 (pt) 2021-02-02
ES2874875T3 (es) 2021-11-05
JP2017513908A (ja) 2017-06-01
EP3906921A1 (en) 2021-11-10
JP2019189646A (ja) 2019-10-31
EP3134084B1 (en) 2021-03-17
KR102474701B1 (ko) 2022-12-05

Similar Documents

Publication Publication Date Title
MX375716B (es) Método para tratar adenocarcinoma de pulmón.
EA201591509A1 (ru) Ингибиторы cdc7
EA201891340A1 (ru) Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек
ZA201605715B (en) Cyclopropylamines as lsd1 inhibitors
LT3277842T (lt) Vėžio pacientų gydymo būdai farneziltransferazės inhibitoriais
NZ724691A (en) Quinoline derivatives as smo inhibitors
SG10201806849WA (en) Cyclopropylamines as lsd1 inhibitors
MX383484B (es) Método para tratar el cáncer.
PH12016500270A1 (en) Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases
MX381994B (es) Inhibidor de janus quinasa.
IL280158A (en) Methods of treating cancer with the PI3K inhibitor, GDC-0077
IL254876A0 (en) Treatment of lung cancer with inhibitors of glutaminase
EA201391114A1 (ru) Способы использования alk-ингибиторов
MX372823B (es) Derivados de ácido borónico.
UY34812A (es) Método para el tratamiento del cáncer de pulmón de células no pequeñas
AU2015267099A8 (en) Use of eribulin in the treatment of cancer
PH12017501879A1 (en) Methods for treating cancer
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
LT3534885T (lt) Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
EA201791099A1 (ru) Хинолин карбоксамиды для применения в лечении лейкоза
EA201692332A1 (ru) Борсодержащие ингибиторы протеасом для применения после первичной противораковой терапии
MX378601B (es) Derivados de dipicolilamina y sus usos farmaceuticos.
EA201891008A3 (ru) Лечение симптомов, связанных с андроген-депривационной терапией
EA201650085A1 (ru) Способ лечения опухолевого заболевания и способ селективного ингибирования роста опухолевых клеток с помощью производного хиноксалин-1,4-диоксида

Legal Events

Date Code Title Description
GD Licence granted
FG Grant or registration